osteoporosis
OSTEOPOROSIS
Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.

Differential Diagnosis

  • Pathological fracture
  • Secondary osteoporosis
Causes of Secondary Osteoporosis
  • Endocrine diseases [eg Cushing’s syndrome, hypogonadism (mostly in men), hyperthyroidism, hyperparathyroidism, type 1 or 2 diabetes, premature menopause, acromegaly, porphyria, growth hormone deficiency, etc]
  • Medications (eg corticosteroids, Heparin, anticonvulsants, immunosuppressants, aromatase inhibitors, gonadotropin-releasing hormone agents, proton pump inhibitors, Medroxyprogesterone, etc)
  • Chronic diseases (eg renal impairment, liver cirrhosis, malabsorption, rheumatoid arthritis, COPD, AIDS/HIV, ankylosing spondylitis, hemophilia, major depression, organ transplantation, Marfan syndrome, osteogenesis imperfecta, etc)
  • Others (eg malnutrition, malignancy, excessive alcohol, prolonged immobility, pregnancy, total parenteral nutrition,etc)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
09 May 2019
Nurses who utilize the pen device take less time preparing and administering insulin compared with those who use the vial and syringe method, reports a recent study.
5 days ago
Excessive gains in overall and central fat prior to the childbearing period pose an increased risk of developing gestational diabetes mellitus, a study has found.
24 Apr 2019
Severe vitamin D deficiency may be detrimental to diabetic patients, with the condition increasing the risk of diabetic foot ulcer, according to the results of a meta-analysis.
5 days ago
New drug applications approved by US FDA as of 01 - 15 May 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.